Td Asset Management Inc Apellis Pharmaceuticals, Inc. Transaction History

Td Asset Management Inc

$106 Billion
Q4 2024

A detailed history of Td Asset Management Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 38,692 shares of APLS stock, worth $939,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,692

Previous 238,212 83.76%

Holding current value

$939,054

Previous $6.87 Million 82.04%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$26.18 - $35.42 $5.22 Million - $7.07 Million	-199,520 Reduced 83.76%	38,692 $1.23 Million
Q3 2024 Nov 01, 2024	SELL	$28.84 - $41.15 $2.12 Million - $3.03 Million	-73,620 Reduced 23.61%	238,212 $6.87 Million
Q2 2024 Aug 02, 2024	SELL	$38.07 - $59.71 $5.62 Million - $8.81 Million	-147,570 Reduced 32.12%	311,832 $12 Million
Q1 2024 May 08, 2024	SELL	$55.39 - $72.47 $1.32 Million - $1.73 Million	-23,920 Reduced 4.95%	459,402 $27 Million
Q4 2023 Feb 12, 2024	BUY	$37.14 - $64.82 $4.18 Million - $7.29 Million	112,465 Added 30.33%	483,322 $28.9 Million
Q3 2023 Oct 27, 2023	SELL	$23.65 - $89.22 $2.55 Million - $9.62 Million	-107,869 Reduced 22.53%	370,857 $14.1 Million
Q2 2023 Aug 09, 2023	BUY	$76.68 - $93.31 $7.73 Million - $9.4 Million	100,758 Added 26.66%	478,726 $43.6 Million
Q1 2023 May 10, 2023	BUY	$46.59 - $66.96 $4.95 Million - $7.12 Million	106,348 Added 39.15%	377,968 $24.9 Million
Q4 2022 Feb 06, 2023	SELL	$43.24 - $61.04 $306,831 - $433,139	-7,096 Reduced 2.55%	271,620 $14 Million
Q3 2022 Nov 07, 2022	BUY	$44.76 - $69.66 $179 - $278	4 Added 0.0%	278,716 $18.2 Million
Q2 2022 Aug 04, 2022	BUY	$35.07 - $59.21 $1.09 Million - $1.84 Million	31,026 Added 12.53%	278,712 $12.6 Million
Q1 2022 May 10, 2022	BUY	$35.46 - $54.12 $3.07 Million - $4.69 Million	86,641 Added 53.8%	247,686 $12.6 Million
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $1.27 Million - $2.03 Million	41,381 Added 34.58%	161,045 $7.61 Million
Q3 2021 Nov 09, 2021	SELL	$31.4 - $69.84 $619,773 - $1.38 Million	-19,738 Reduced 14.16%	119,664 $3.94 Million
Q2 2021 Aug 11, 2021	BUY	$40.9 - $64.9 $1.5 Million - $2.39 Million	36,779 Added 35.84%	139,402 $8.92 Million
Q1 2021 May 14, 2021	BUY	$40.8 - $57.39 $1.07 Million - $1.5 Million	26,180 Added 34.25%	102,623 $4.4 Million
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $298,663 - $554,840	9,700 Added 14.53%	76,443 $4.37 Million
Q2 2020 Aug 13, 2020	BUY	$24.8 - $38.49 $880,400 - $1.37 Million	35,500 Added 113.63%	66,743 $2.18 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $151,840 - $375,829	8,478 Added 37.24%	31,243 $837,000
Q3 2019 Nov 07, 2019	BUY	$24.09 - $32.18 $140,300 - $187,416	5,824 Added 34.38%	22,765 $548,000
Q1 2019 May 08, 2019	SELL	$12.81 - $19.82 $37,149 - $57,478	-2,900 Reduced 14.62%	16,941 $330,000
Q4 2018 Feb 01, 2019	BUY	$11.47 - $18.71 $4,588 - $7,484	400 Added 2.06%	19,841 $262,000
Q2 2018 Jul 31, 2018	BUY	$19.63 - $30.0 $381,626 - $583,230	19,441 New	19,441 $428,000

Others Institutions Holding APLS

# of Institutions

300

Shares Held

111M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Apellis Pharmaceuticals, Inc. Transaction History